Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of oral deferasirox (20 mg/kg/d) in pts 3 to 6 months after allogeneic hematopoietic cell transplantation who present with iron overload

Conditions: Iron Overload

Summary: the purpose of this study is to investigate the effects of iron chelation using deferasirox in patients who show signs of iron overload after an allogeneic stem cell transplantation the iron overload must be due to blood transfusions.


Eligibility criteria:
inclusion criteria: 1. transfusional iron overload three to six months after hct with no evidence of active inflammation 2. history of at least 20 units of red blood cell transfusions or 100ml/kg of prepacked red blood cells (prbcs). 3. patients of either gender and age ≥ 18 years. 4. female patients who have reached menarche and who are sexually active must use double-barrier contraception, oral contraceptive plus barrier contraception , or must have undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation or be postmenopausal defined by amenorrhea for at least 12 months. exclusion criteria: 1. non-transfusion related iron overload 2. active malignancy 3. known active viral hepatitis or known hiv positiveness 4. mean levels of alanine aminotransferase (alt) \> 5x uln 5. treatment with any iron chelator after transplantation 6. uncontrolled systemic hypertension 7. serum creatinine \> 1.5 uln and/or serum creatinine clearance \< 60 ml/min 8. history of nephrotic syndrome. 9. previous history of clinically relevant ocular or auditory toxicity related to iron chelation. 10. systemic diseases (cardiovascular, renal, hepatic, etc.) which would prevent the patient from undergoing study treatment 11. pregnant or breast feeding patients. other protocol-defined inclusion/exclusion criteria may apply

Keywords: hematopoietic stem cell transplantation hct iron overload chelators icl670 deferasirox serum ferritin lic transfusional hemosiderosis blood transfusions adults iron chelation 3-6 months allogeneic hematopoietic stem cell transplantation
efficacy of lutein, zeaxanthine and trypan blue to stain the anterior lens capsule

Conditions: Cataract

Summary: effectiveness of lutein, zeaxanthin and trypan blue to stain the anterior lens capsule during cataract phacoemulsification.

twenty patients with cataract (nuclear, entumecente, total) and indication for cataract surgery will be selected to participate in this study.

Eligibility criteria:
inclusion criteria * patients over 50 years * diagnosis of cataract (nuclear, entumecente, total) * absence of red reflex * indication of cataract surgery exclusion criteria * posterior subcapsular cataract * any history of eye disease * glaucoma * eye infection affecting any structure prior ocular * any previous ocular surgery

Keywords: lutein zeaxanthin trypan blue dye
gepirone vs placebo in treatment of cocaine dependence - 3

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to test antidepressant medication, gepirone, as a pharmacotherapy for cocaine dependent subjects.


Eligibility criteria:
please contact site for information.

Keywords: cocaine dependence gepirone
effect of prewarming during induction of general anesthesia combined with warmed intravenous fluid on core temperature.

Conditions: Urologic Diseases

Summary: hypothermia occurs frequently during general anesthesia. this study is to evaluate the efficacy of 10 minutes of prewarming during induction of general anesthesia during urologic surgery.

hypothermia is of continuous issue in patients undergoing general anesthesia. during urologic operation (transurethral resection of bladder and prostate), bladder irrigation worsens hypothermia. hence, various methods including prewarming of the patient are used to maintain core temperature during operation. prewarming is found to be effective in maintaining core temperature perioperatively by increasing peripheral tissue heat content. however, applying more than 30 minutes of prewarming may be impractical as a clinical routine practice. hence, developing simple and effective method to prevent hypothermia is expected. here, the investigators planned to examine the effect of active warming (10 minutes of warming during induction of general anesthesia and prewarmed intravenous fluid intraoperatively) on hypothermia in patients undergoing urologic operation under general anesthesia.

Eligibility criteria:
inclusion criteria: * patients undergoing urologic surgery(transurethral resection of bladder, prostate) exclusion criteria: * moderate to severe cardiopulmonary, renal impairment * previous thyroid disease * any infection sign * abnormal temperature prior to induction of general anesthesia (\ 37.5'c) * refusal to participate in the study * unable to understand the study
the cost-effectiveness of screening for diabetic retinopathy in hong kong

Conditions: Diabetic Retinopathy

Summary: introduction: there is no debate that people with diabetes should be screened for the development of retinopathy which can threaten their sight. however, there is no routine screening for retinopathy in hong kong at present. many overseas countries find that they miss a large proportion of their target population and, with reliance on co-payments for screening, as is the case with the limited opportunistic screening at present, the cost-effectiveness of any routine service in hong kong could be reduced as is predicted by hart's inverse care law. aim: this study will determine the potential cost-effectiveness of screening for retinopathy in hong kong under a free system and one in which a co-payment is charged. methods: primary care patients attending general outpatient clinics on hong kong island for their routine diabetic care will randomly be offered screening either at no charge or with the normal co-payment of $65. those who are willing and unwilling to be screened will be compared for their clinical, lifestyle and socioeconomic characteristics and those unwilling will be asked their reasons. the uptake of screening at no fee and with a payment will be compared as will the prevalence of retinopathy in the two fee groups. subsequent screening at one year will be offered at the same fee and uptake again compared. the principal analyses will (a) identify the characteristics of those willing to be screened and reasons for not being screened (b) the uptake of screening when a co-payment is charged compared to when it is free (c) whether there is a difference in the prevalence of retinopathy between the group willing to pay and those who accept free screening and (d) the uptake of re-screening in year 2. the resulting cost-effectiveness model will use these data, the cost data collected during the study and overseas data on benefits of treatment to model the cost-effectiveness of screening for retinopathy in hong kong if it were to be offered free or with a co-payment. this information will be important to determine the most cost-effective means of implementing this preventative strategy to preserve sight and quality of life.


Eligibility criteria:
inclusion criteria: * all diabetic patients who attend the clinic during the study period. exclusion criteria: * only if not competent to give informed consent

Keywords: diabetic retinopathy screening co-payment health service
evaluation of the treatment response in breast cancer related lymphedema

Conditions: Lymphedema of Upper Limb; Breast Cancer; Breast Cancer Lymphedema

Summary: this study aims to evaluate the effects of the treatment for breast cancer lymphedema. after taking a detailed history and giving a physical examination, breast cancer related lymphedema patients(n:30) will be informed and will be given complete decongestive therapy, which includes decongestive exercises, manual lymphatic drainage, compression therapy(either through short stretch bandaging and/or pneumatic device) and exercise. patients will be evaluated with limb volume, lymphedema index acquired through bioimpedance device, quickdash for upper extremity function, hand dynamometer for upper extremity grip strength and clue(breast cancer-related lymphedema of the upper extremity standardized clinical evaluation tool) scoring for lymphedema before and after the intervention. the values will be compared in order to show whether there are significant differences between before and after scores, and whether clue score is correlated with the other indicators of breast cancer related lymphedema.


Eligibility criteria:
inclusion criteria: * unilateral lymphedema of the arm after mastectomy for breast cancer exclusion criteria: * bilateral lymphedema * primary bone tumor and/or metastasis * patients with ongoing radiotherapy * circulation disorders of the upper extremity(eg; peripheral vascular disease, thrombosis) * patients with infectious lymphedema/elephantiasis * presence of local infection in upper extremities(cellulitis) and/or presence of severe systemic infection * carcinomatous lymphangitis * congestive heart failure(nyha class 3 or 4) * history of prosthesis on upper extremities * use of drugs which may alter the fluid or electrolyte balance

Keywords: lymphedema mastectomy breast cancer
the development of psychiatric non-suicidal self-injury risk assessment scale

Conditions: Non Suicidal Self Injury

Summary: non-suicidal self-injury (nssi) is a growing global mental health challenge, distinct from suicidal behavior, with unique risk factors and mechanisms. existing risk assessment tools do not focus on differentiating nssi from suicidal self-harm or comprehensively evaluate risk and protective factors specific to nssi. there is a lack of clinically applicable, validated scales dedicated to assessing nssi risk, particularly in psychiatric populations. the present study is made to design the psychiatric non-suicidal self-injury risk assessment scale, a 39-item scale that evaluates static/dynamic risk factors and protective factors for nssi in psychiatric patients.

the initial item pool was created through literature review, semi-structured interviews, and group discussions. two rounds of the delphi were employed with twenty experts. we analyzed items using critical ratio, correlation coefficient, factor analysis, and cronbach's α coefficient. exploratory factor analysis determined item weights, while reliability analyses evaluated internal consistency, test-retest, inter-observer and split-half methods. in the validity analyses, cvi, construct validity and criterion validity were used. roc curve established the optimal diagnostic threshold and the risk stratification was performed.

Eligibility criteria:
inclusion criteria: 1. criteria for inclusion in the sample were individuals , diagnosed with various mental disorders according to the international classification of diseases, 10th revision (icd-10) diagnostic criteria; 2. gender is not limited and aged is 12-30 years old; 3. the patient's clinical profile is complete and the medical history is detailed; 4. informed consent from patients or guardians who signed a consent for. exclusion criteria: the patient's clinical profile was incomplete and her medical history was not detailed.

Keywords: non-suicidal self-injury risk assessment scale development delphi method reliability validity nursing
pilot study: stress reduction in caregivers of children with asd using act

Conditions: Caregiver Stress

Summary: parents/caregivers of children with autism need psychological flexibility and self-efficacy for the act program to be effective. this study will compare intervention differences between groups. repeated measures will be given three times (pre-intervention, post-intervention, and follow-up) to an act intervention group and a support group (control). the purpose of the present study is to compare the effects of a brief act-based workshop for parents of children with autism with a concurrent parent support control group using a variety of self-report measures addressing psychological flexibility, depression, thought suppression, cognitive fusion, positive aspects of caregiving, stress, self-compassion, and valued living.


Eligibility criteria:
inclusion criteria: * individuals will be eligible for entry if (1) they are the biological or adoptive parent (and primary caregiver) of a child with a diagnosis of an autism spectrum disorder, (2) the child is 2-17 years of age inclusive, (3) speak english, and (4) they plan to live in the area for at least six months and (5) present proof of vaccination and (6) agree to masking and social distancing during the in-person workshop. exclusion criteria: * individuals will be excluded from the study if (1) they are involved in a concurrent clinical trial of psychosocial interventions for parents/caregivers or (2) they (or their child/spouse) indicate during telephone screening or on the demographics questionnaire active major medical issues such as cancer, organ transplant, or severe mental health disorders that prevent active participation.

Keywords: caregivers of children with autism and stress
behavioral and pharmacological reconsolidation interference in misophonia

Conditions: Misophonia

Summary: one of the core processes presumably underlying misophonia - a condition characterized by decreased tolerance for specific sounds - is associative learning. using behavioral, computational, and neural analyses of emotional learning and memory processes to understand the unknown behavioral and neural mechanisms underlying misophonia's associative learning and memory, the study team will evaluate whether interference with the reconsolidation of a reactivated misophonia memory with propranolol can alleviate aversive reaction to misophonia-related cues.


Eligibility criteria:
inclusion criteria: * hypersensitive to presence of a specific sound, which may be accompanied by irritation, anger/outbursts, or fear. * must be between the ages of 18 - 55. * must be fluent in english since the study's instructions, surveys, and tasks will be in english exclusion criteria: * disability or medical condition that prohibits completion of study. participants must be able to complete all study procedures to ensure optimal conditions for data analysis. * cns disease, such as history of brain abnormalities (e.g., neoplasms, subarachnoid cysts), cerebrovascular disease, infectious disease (e.g., abscess), or other neurological disease, history of head trauma (defined as loss of consciousness\>3 min), or history of seizures without a resolved etiology. cns disease and drugs that act in the peripheral or central nervous system are likely to have effects on patterns of neural activity. we wish to minimize confounding variables. * recently used drugs of abuse. * pregnancy. the risks associated with neither propranolol exposure during gestation have been studied extensively. we wish to safeguard the health of potential participants and their children. * lactation. propranolol is excreted in human breast-milk, and its impact on infant development has not been studied. we wish to safeguard the health of potential participants and their children. * regular use of medication metabolized in the cyp2d6, 1a2, or 2c19 pathways. drugs that are metabolized in the same pathway as propranolol may increase its efficacy or toxicity. we wish to safeguard the health of participants. * blood pressure over 150/100 or under 100/60 (applicable for either systolic or diastolic measures) and any hypertension requiring medication. propranolol is known to pose additional risk to individuals with a number of medical conditions. we wish to safeguard the health of our participants. * pulse over 100 or under 55. * history of cardiovascular illness such as cardiac arrhythmia, coronary heart disease or any cardiac dysfunction that requires medication. * active respiratory illness including bronchospastic pulmonary disease and chronic obstructive pulmonary disease * diabetes mellitus. * other medical conditions that make it unsafe to take propranolol (e. g. allergy to propranolol).
the effects of rhus coriaria l. on body weight

Conditions: Body Weight

Summary: the aim of this study is to evaluate the effects of rhus coriaria l. (rhus) commonly known as "somagh" on body weight.

rhus coriaria l.(rhus) is a well-known spice widely consumed in the world which has also been utilized extensively for medicinal purposes. the antioxidant components of this plant made it a favorable target for laboratory and animal studies in different conditions such as oxidative stress cytotoxicity, diabetes and hyperlipidemia. rhus (somagh) is found in temperate and tropical regions worldwide, often growing in areas of marginal agricultural capacity. rhus is used as an herbal remedy in traditional medicine because of its assumed analgesic, antidiarrheic, antiseptic, anorexic and antihyperglycemic properties. the fruits of rhus contain flavonols, phenolic acids, hydrolysable tannins, anthocyans and organic acids such as malice, citric and tartaric acids. some studies have shown that polyphenols could have beneficial effects on cardiovascular disease and cancer and could be regarded as bioactive compounds with a high potential health-promoting capacity. phenolic compounds inhibit lipid peroxidation, scavenge the superoxide anion and hydroxyl radical, and enhance the activities of detoxifying enzymes. the aim of this study is to evaluate the effects of rhus coriaria l. (rhus) commonly known as somagh on body weight.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) \>= 25 kg/m2 exclusion criteria: * diabetes mellitus * hypo. or hyperthyroidism * any systemic illnesses e.g. liver cirrhosis, acute or chronic renal failure, heart failure * use of drugs: weight lowering agents, glucocorticoids, oral contraceptive pills. * pregnancy * history of allergic reaction to somagh

Keywords: body weight changes medicine, traditional herbal medicine rhus waist circumference waist-hip ratio body mass index
study of inotuzumab ozogamicin + temsirolimus in patients with relapsed or refractory cd22+ b-cell nhlymphoma

Conditions: B-cell Lymphoma Refractory

Summary: this is an open label phase i study of inotuzumab ozogamicin, an antibody-targeted intravenous chemotherapy agent composed of a cd22-targeted antibody linked to calicheamicin, in combination with the mammalian target of rapamycin (mtor) inhibitor temsirolimus, in patients with relapsed/refractory cd22+ b-cell non hodgkin's lymphomas (nhls). both inotuzumab ozogamicin and temsirolimus have been evaluated as single agents as well as in combination with rituximab in patients with nhls. this is the first study combining the two agents together. in the present study inotuzumab ozogamicin will be administered intravenously on d1 at the starting dose of 0.8 /m2. temsirolimus will be administered intravenously on days 1,8,15 and 22 at the starting dose of 15mg. cycles will be repeated every 28 days.


Eligibility criteria:
key inclusion criteria * histologically and/or cytologically confirmed relapsed or refractory cd22+ b-cell non hodgkin's lymphomas * no limitations on prior treatments. patients must have progressed after at least one prior therapy. * adult patients (aged \> 18yrs old). * ecog status ≤ 1. * life expectancy greater than 3 months. * adequate organ and marrow function. key exclusion criteria * uncontrolled intercurrent illness * chronic obstructive or chronic restrictive pulmonary disease * hepatitis b, c and hiv * patients with known known central nervous system lymphoma involvement.

Keywords: b-cell non hodgkin's lymphomas cd22 positive
anticoagulation therapy after splenectomy in cirrhosis patient

Conditions: Liver Cirrhosis; Portal Hypertension; Anticoagulant-induced Bleeding; Thrombosis

Summary: 1. inclusion and exclusion criteria inclusion criteria: inpatients who received laparotomy or laparoscopic splenectomy according to clinical, b-ultrasound scan, ct or mri diagnosis of cirrhosis and portal hypertension. exclusion criteria: 1. ) portal vein system thrombosis (pvst) found by preoperative color doppler ultrasound or mri examination; 2. ) liver cirrhosis complicated with liver tumor; 3. ) liver cirrhosis complicated with blood system diseases; 4. ) patients who have not signed the informed consent form. 2. research subgroup according to the order of the patients, the following groups are entered in turn, and the cycle is repeated. 1. ) heparin group 2. ) rivaroxaban group 3. ) control group.

1. inclusion and exclusion criteria inclusion criteria: inpatients who received laparotomy or laparoscopic splenectomy according to clinical, b-ultrasound scan, ct or mri diagnosis of cirrhosis and portal hypertension. exclusion criteria: 1. ) portal vein system thrombosis (pvst) found by preoperative color doppler ultrasound or mri examination; 2. ) liver cirrhosis complicated with liver tumor; 3. ) liver cirrhosis complicated with blood system diseases; 4. ) patients who have not signed the informed consent form. 2. research subgroup according to the order of the patients, the following groups are entered in turn, and the cycle is repeated. 1. ) heparin group: low molecular weight heparin 5000u ih q12h was given 24 hours after operation, 5 days after operation. warfarin 1.25-2.5 mg po qd, 30 days after operation. pt（prothrombin time）/inr（international normalized ratio） was kept at 1.25-1.5. 2. ) rivaroxaban group: rivaroxaban 10mg po qd from 24 hours after operation, 30 days after operation. pt/inr was kept at 1.25-1.5. 3. ) control group: no preventive intervention measures. if platelets in the above groups are \> 500× 109/l, aspirin 100 mg qd is added for 1 month. if platelets are \> 1000× 109/l, platelet collection is performed. 3. monitoring indicators color doppler ultrasound was reexamined 1, 2, 3 and 4 weeks after operation to find out whether pvst was present. abdominal ct was performed when pvst was suspected. after the patient's condition is stable, the portal vein system ultrasound is reviewed monthly, and the follow-up time is 1 year.

Eligibility criteria:
inclusion criteria: * inpatients who received laparotomy or laparoscopic splenectomy according to clinical, b-ultrasound scan, ct or mri diagnosis of cirrhosis and portal hypertension exclusion criteria: * portal vein thrombosis found by preoperative color doppler ultrasound or mri examination; * liver cirrhosis complicated with liver tumor; * liver cirrhosis complicated with blood system diseases; * patients who have not signed the informed consent form.